163 related articles for article (PubMed ID: 25229924)
1. Dalbavancin or oritavancin for skin infections.
Baang J; Fisher S
N Engl J Med; 2014 Sep; 371(12):1160-1. PubMed ID: 25229924
[No Abstract] [Full Text] [Related]
2. Dalbavancin or oritavancin for skin infections.
Corey GR; Jiang H; Moeck G
N Engl J Med; 2014 Sep; 371(12):1162-3. PubMed ID: 25243251
[No Abstract] [Full Text] [Related]
3. Dalbavancin or oritavancin for skin infections.
Núñez-Núñez M; Rodríguez-Baño J
N Engl J Med; 2014 Sep; 371(12):1160. PubMed ID: 25229923
[No Abstract] [Full Text] [Related]
4. Dalbavancin or oritavancin for skin infections.
Boucher HW; Talbot GH; Dunne MW
N Engl J Med; 2014 Sep; 371(12):1161-2. PubMed ID: 25229922
[No Abstract] [Full Text] [Related]
5. Dalbavancin or oritavancin for skin infections.
Cormican M
N Engl J Med; 2014 Sep; 371(12):1161. PubMed ID: 25229925
[No Abstract] [Full Text] [Related]
6. Pharmacology and the treatment of complicated skin and skin-structure infections.
Chambers HF
N Engl J Med; 2014 Jun; 370(23):2238-9. PubMed ID: 24897088
[No Abstract] [Full Text] [Related]
7. Weekly dalbavancin was noninferior to daily vancomycin for acute bacterial skin infection in adults.
Zervou FN; Zacharioudakis IM; Mylonakis E
Ann Intern Med; 2014 Oct; 161(8):JC9. PubMed ID: 25329226
[No Abstract] [Full Text] [Related]
8. Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections.
Roberts KD; Sulaiman RM; Rybak MJ
Pharmacotherapy; 2015 Oct; 35(10):935-48. PubMed ID: 26497480
[TBL] [Abstract][Full Text] [Related]
9. Single-dose oritavancin in the treatment of acute bacterial skin infections.
Corey GR; Kabler H; Mehra P; Gupta S; Overcash JS; Porwal A; Giordano P; Lucasti C; Perez A; Good S; Jiang H; Moeck G; O'Riordan W;
N Engl J Med; 2014 Jun; 370(23):2180-90. PubMed ID: 24897083
[TBL] [Abstract][Full Text] [Related]
10. Once-weekly dalbavancin versus daily conventional therapy for skin infection.
Boucher HW; Wilcox M; Talbot GH; Puttagunta S; Das AF; Dunne MW
N Engl J Med; 2014 Jun; 370(23):2169-79. PubMed ID: 24897082
[TBL] [Abstract][Full Text] [Related]
11. Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis.
Agarwal R; Bartsch SM; Kelly BJ; Prewitt M; Liu Y; Chen Y; Umscheid CA
Clin Microbiol Infect; 2018 Apr; 24(4):361-368. PubMed ID: 28882727
[TBL] [Abstract][Full Text] [Related]
12. Role or oritavancin and dalbavancin in acute bacterial skin and skin structure infections and other potential indications.
Bassetti M; Labate L; Vena A; Giacobbe DR
Curr Opin Infect Dis; 2021 Apr; 34(2):96-108. PubMed ID: 33405480
[TBL] [Abstract][Full Text] [Related]
13. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
Guskey MT; Tsuji BT
Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
[TBL] [Abstract][Full Text] [Related]
14. Reply to DiNubile.
Corey GR; Boucher HW; Stryjewski ME
Clin Infect Dis; 2015 Apr; 60(8):1291-2. PubMed ID: 25609681
[No Abstract] [Full Text] [Related]
15. Trials and tribulations of noninferiority: caveat emptor.
DiNubile MJ
Clin Infect Dis; 2015 Apr; 60(8):1290-1. PubMed ID: 25609683
[No Abstract] [Full Text] [Related]
16. Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State.
Belley A; Lalonde Seguin D; Arhin F; Moeck G
Antimicrob Agents Chemother; 2016 Jul; 60(7):4342-5. PubMed ID: 27067327
[TBL] [Abstract][Full Text] [Related]
17. New Gram Positive Agents to Treat Acute Bacterial Skin and Skin Structure Infections.
Li R; Nailor MD
Conn Med; 2016 Mar; 80(3):175-80. PubMed ID: 27169303
[TBL] [Abstract][Full Text] [Related]
18. New antibiotics in the management of acute bacterial skin and skin structure infections.
Gleghorn K; Grimshaw E; Kelly EK
Skin Therapy Lett; 2015; 20(5):7-9. PubMed ID: 26382907
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections.
Galluzzo M; D'Adamio S; Bianchi L; Talamonti M
Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):197-206. PubMed ID: 29258361
[TBL] [Abstract][Full Text] [Related]
20. Beyond Vancomycin: The Tail of the Lipoglycopeptides.
Klinker KP; Borgert SJ
Clin Ther; 2015 Dec; 37(12):2619-36. PubMed ID: 26658277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
